Revance Therapeutics Inc [NASDAQ: RVNC] closed the trading session at $6.91 on 11/09/23. The day’s price range saw the stock hit a low of $6.83, while the highest price level was $8.50. The company report on November 8, 2023 at 4:06 PM that Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update.
– Q3 total product revenue of $54.1 million, a YoY increase of 107.5%.– Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million.– Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%.– In August, DAXXIFY was approved by the FDA for the treatment of cervical dystonia, representing the company’s first approval in the therapeutics market.– DAXXIFY cervical dystonia PrevU program remains on track with over 150 patients treated.– Conference call and webcast today at 4:30 p.m. ET.
Revance Therapeutics, Inc. (RVNC), today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
The stocks have a year to date performance of -62.57 percent and weekly performance of -18.13 percent. The stock has been moved at -80.66 percent over the last six months. The stock has performed -30.27 percent around the most recent 30 days and changed -63.46 percent over the most recent 3-months.
If compared to the average trading volume of 2.00M shares, RVNC reached to a volume of 3651612 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Revance Therapeutics Inc [RVNC]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RVNC shares is $33.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RVNC stock is a recommendation set at 1.42. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Exane BNP Paribas have made an estimate for Revance Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 16, 2023.
The Average True Range (ATR) for Revance Therapeutics Inc is set at 0.73, with the Price to Sales ratio for RVNC stock in the period of the last 12 months amounting to 3.26. The Price to Book ratio for the last quarter was 22.69, with the Price to Cash per share for the same quarter was set at 3.64.
RVNC stock trade performance evaluation
Revance Therapeutics Inc [RVNC] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -18.13. With this latest performance, RVNC shares dropped by -30.27% in over the last four-week period, additionally sinking by -80.66% over the last 6 months – not to mention a drop of -67.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RVNC stock in for the last two-week period is set at 28.26, with the RSI for the last a single of trading hit 27.13, and the three-weeks RSI is set at 28.31 for Revance Therapeutics Inc [RVNC]. The present Moving Average for the last 50 days of trading for this stock 11.50, while it was recorded at 8.43 for the last single week of trading, and 24.52 for the last 200 days.
Revance Therapeutics Inc [RVNC]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Revance Therapeutics Inc [RVNC] shares currently have an operating margin of -205.31 and a Gross Margin at +35.58. Revance Therapeutics Inc’s Net Margin is presently recorded at -268.87.
Return on Total Capital for RVNC is now -66.06, given the latest momentum, and Return on Invested Capital for the company is -87.53. Return on Equity for this stock declined to -879.28, with Return on Assets sitting at -64.04. When it comes to the capital structure of this company, Revance Therapeutics Inc [RVNC] has a Total Debt to Total Equity ratio set at 3,321.17. Additionally, RVNC Total Debt to Total Capital is recorded at 97.08, with Total Debt to Total Assets ending up at 71.91. Long-Term Debt to Equity for the company is recorded at 3,282.19, with the Long-Term Debt to Total Capital now at 95.94.
Reflecting on the efficiency of the workforce at the company, Revance Therapeutics Inc [RVNC] managed to generate an average of -$667,457 per employee. Receivables Turnover for the company is 18.05 with a Total Asset Turnover recorded at a value of 0.24.Revance Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.65 and a Current Ratio set at 5.12.
Earnings per share (EPS) analysis for Revance Therapeutics Inc [RVNC] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RVNC. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Revance Therapeutics Inc go to 11.60%.
Revance Therapeutics Inc [RVNC]: Institutional Ownership
The top three institutional holders of RVNC stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in RVNC stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in RVNC stock with ownership which is approximately 5.7994%.